 | • レポートコード：MRC2-11QY12547 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は肺がん診断・治療のグローバル市場について調査・分析したレポートです。種類別（非小細胞肺がん、小細胞肺がん）市場規模、用途別（病院、がん研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別肺がん診断・治療の競争状況、市場シェア ・世界の肺がん診断・治療市場：種類別市場規模 2015年-2020年（非小細胞肺がん、小細胞肺がん） ・世界の肺がん診断・治療市場：種類別市場規模予測 2021年-2026年（非小細胞肺がん、小細胞肺がん） ・世界の肺がん診断・治療市場：用途別市場規模 2015年-2020年（病院、がん研究センター） ・世界の肺がん診断・治療市場：用途別市場規模予測 2021年-2026年（病院、がん研究センター） ・北米の肺がん診断・治療市場分析：米国、カナダ ・ヨーロッパの肺がん診断・治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの肺がん診断・治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の肺がん診断・治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの肺がん診断・治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Eli Lilly、Sanofi、ArQule、Daiichi Sankyo、Celgene、Merck、Pfizer、Boehringer Ingelheim、Roche、Genentech、GSK、Pharmacyclics、Novartis、Bayer、Bristol-Myers Squibb、Eisai、AbbVie ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung.
Robust healthcare expenditure within the developed countries, increasing pollution, government initiatives for lung cancer, and rising cases of smoking are some of the major factors that fuel the growth of the market.
Market Analysis and Insights: Global Lung Cancer Diagnosis and Therapeutics Market
The global Lung Cancer Diagnosis and Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Lung Cancer Diagnosis and Therapeutics Scope and Market Size
Lung Cancer Diagnosis and Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Lung Cancer Diagnosis and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AstraZeneca
Eli Lilly
Sanofi
ArQule
Daiichi Sankyo
Celgene
Merck
Pfizer
Boehringer Ingelheim
Roche
Genentech
GSK
Pharmacyclics
Novartis
Bayer
Bristol-Myers Squibb
Eisai
AbbVie
Market segment by Type, the product can be split into
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Market segment by Application, split into
Hospitals
Cancer Research Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Lung Cancer Diagnosis and Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Lung Cancer Diagnosis and Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Non-Small Cell Lung Cancer
1.4.3 Small Cell Lung Cancer
1.5 Market by Application
1.5.1 Global Lung Cancer Diagnosis and Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Diagnosis and Therapeutics Market Perspective (2015-2026)
2.2 Global Lung Cancer Diagnosis and Therapeutics Growth Trends by Regions
2.2.1 Lung Cancer Diagnosis and Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Lung Cancer Diagnosis and Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Lung Cancer Diagnosis and Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Lung Cancer Diagnosis and Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Market Size
3.1.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Lung Cancer Diagnosis and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio
3.2.1 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnosis and Therapeutics Revenue in 2019
3.3 Lung Cancer Diagnosis and Therapeutics Key Players Head office and Area Served
3.4 Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
3.5 Date of Enter into Lung Cancer Diagnosis and Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
5.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
6.2 Lung Cancer Diagnosis and Therapeutics Key Players in North America (2019-2020)
6.3 North America Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
6.4 North America Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
7.2 Lung Cancer Diagnosis and Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
7.4 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
8.2 Lung Cancer Diagnosis and Therapeutics Key Players in China (2019-2020)
8.3 China Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
8.4 China Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
9.2 Lung Cancer Diagnosis and Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
9.4 Japan Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
10.2 Lung Cancer Diagnosis and Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
11.2 Lung Cancer Diagnosis and Therapeutics Key Players in India (2019-2020)
11.3 India Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
11.4 India Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Lung Cancer Diagnosis and Therapeutics Market Size (2015-2020)
12.2 Lung Cancer Diagnosis and Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Lung Cancer Diagnosis and Therapeutics Introduction
13.1.4 AstraZeneca Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Lung Cancer Diagnosis and Therapeutics Introduction
13.2.4 Eli Lilly Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 Sanofi
13.3.1 Sanofi Company Details
13.3.2 Sanofi Business Overview
13.3.3 Sanofi Lung Cancer Diagnosis and Therapeutics Introduction
13.3.4 Sanofi Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.3.5 Sanofi Recent Development
13.4 ArQule
13.4.1 ArQule Company Details
13.4.2 ArQule Business Overview
13.4.3 ArQule Lung Cancer Diagnosis and Therapeutics Introduction
13.4.4 ArQule Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.4.5 ArQule Recent Development
13.5 Daiichi Sankyo
13.5.1 Daiichi Sankyo Company Details
13.5.2 Daiichi Sankyo Business Overview
13.5.3 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Introduction
13.5.4 Daiichi Sankyo Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.5.5 Daiichi Sankyo Recent Development
13.6 Celgene
13.6.1 Celgene Company Details
13.6.2 Celgene Business Overview
13.6.3 Celgene Lung Cancer Diagnosis and Therapeutics Introduction
13.6.4 Celgene Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.6.5 Celgene Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Lung Cancer Diagnosis and Therapeutics Introduction
13.7.4 Merck Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview
13.8.3 Pfizer Lung Cancer Diagnosis and Therapeutics Introduction
13.8.4 Pfizer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Details
13.9.2 Boehringer Ingelheim Business Overview
13.9.3 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Introduction
13.9.4 Boehringer Ingelheim Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.9.5 Boehringer Ingelheim Recent Development
13.10 Roche
13.10.1 Roche Company Details
13.10.2 Roche Business Overview
13.10.3 Roche Lung Cancer Diagnosis and Therapeutics Introduction
13.10.4 Roche Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
13.10.5 Roche Recent Development
13.11 Genentech
10.11.1 Genentech Company Details
10.11.2 Genentech Business Overview
10.11.3 Genentech Lung Cancer Diagnosis and Therapeutics Introduction
10.11.4 Genentech Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.11.5 Genentech Recent Development
13.12 GSK
10.12.1 GSK Company Details
10.12.2 GSK Business Overview
10.12.3 GSK Lung Cancer Diagnosis and Therapeutics Introduction
10.12.4 GSK Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.12.5 GSK Recent Development
13.13 Pharmacyclics
10.13.1 Pharmacyclics Company Details
10.13.2 Pharmacyclics Business Overview
10.13.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Introduction
10.13.4 Pharmacyclics Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.13.5 Pharmacyclics Recent Development
13.14 Novartis
10.14.1 Novartis Company Details
10.14.2 Novartis Business Overview
10.14.3 Novartis Lung Cancer Diagnosis and Therapeutics Introduction
10.14.4 Novartis Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.14.5 Novartis Recent Development
13.15 Bayer
10.15.1 Bayer Company Details
10.15.2 Bayer Business Overview
10.15.3 Bayer Lung Cancer Diagnosis and Therapeutics Introduction
10.15.4 Bayer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.15.5 Bayer Recent Development
13.16 Bristol-Myers Squibb
10.16.1 Bristol-Myers Squibb Company Details
10.16.2 Bristol-Myers Squibb Business Overview
10.16.3 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Introduction
10.16.4 Bristol-Myers Squibb Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.16.5 Bristol-Myers Squibb Recent Development
13.17 Eisai
10.17.1 Eisai Company Details
10.17.2 Eisai Business Overview
10.17.3 Eisai Lung Cancer Diagnosis and Therapeutics Introduction
10.17.4 Eisai Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.17.5 Eisai Recent Development
13.18 AbbVie
10.18.1 AbbVie Company Details
10.18.2 AbbVie Business Overview
10.18.3 AbbVie Lung Cancer Diagnosis and Therapeutics Introduction
10.18.4 AbbVie Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020)
10.18.5 AbbVie Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Lung Cancer Diagnosis and Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Lung Cancer Diagnosis and Therapeutics Revenue
Table 3. Ranking of Global Top Lung Cancer Diagnosis and Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Lung Cancer Diagnosis and Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Non-Small Cell Lung Cancer
Table 6. Key Players of Small Cell Lung Cancer
Table 7. Global Lung Cancer Diagnosis and Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Lung Cancer Diagnosis and Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Lung Cancer Diagnosis and Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Lung Cancer Diagnosis and Therapeutics Market Share by Regions (2015-2020)
Table 11. Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Lung Cancer Diagnosis and Therapeutics Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Lung Cancer Diagnosis and Therapeutics Market Growth Strategy
Table 17. Main Points Interviewed from Key Lung Cancer Diagnosis and Therapeutics Players
Table 18. Global Lung Cancer Diagnosis and Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 19. Global Lung Cancer Diagnosis and Therapeutics Market Share by Players (2015-2020)
Table 20. Global Top Lung Cancer Diagnosis and Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lung Cancer Diagnosis and Therapeutics as of 2019)
Table 21. Global Lung Cancer Diagnosis and Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
Table 24. Date of Enter into Lung Cancer Diagnosis and Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 27. Global Lung Cancer Diagnosis and Therapeutics Market Size Share by Type (2015-2020)
Table 28. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Type (2021-2026)
Table 29. Global Lung Cancer Diagnosis and Therapeutics Market Size Share by Application (2015-2020)
Table 30. Global Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 31. Global Lung Cancer Diagnosis and Therapeutics Market Size Share by Application (2021-2026)
Table 32. North America Key Players Lung Cancer Diagnosis and Therapeutics Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Lung Cancer Diagnosis and Therapeutics Market Share (2019-2020)
Table 34. North America Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 35. North America Lung Cancer Diagnosis and Therapeutics Market Share by Type (2015-2020)
Table 36. North America Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 37. North America Lung Cancer Diagnosis and Therapeutics Market Share by Application (2015-2020)
Table 38. Europe Key Players Lung Cancer Diagnosis and Therapeutics Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Lung Cancer Diagnosis and Therapeutics Market Share (2019-2020)
Table 40. Europe Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Lung Cancer Diagnosis and Therapeutics Market Share by Type (2015-2020)
Table 42. Europe Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Lung Cancer Diagnosis and Therapeutics Market Share by Application (2015-2020)
Table 44. China Key Players Lung Cancer Diagnosis and Therapeutics Revenue (2019-2020) (Million US$)
Table 45. China Key Players Lung Cancer Diagnosis and Therapeutics Market Share (2019-2020)
Table 46. China Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 47. China Lung Cancer Diagnosis and Therapeutics Market Share by Type (2015-2020)
Table 48. China Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 49. China Lung Cancer Diagnosis and Therapeutics Market Share by Application (2015-2020)
Table 50. Japan Key Players Lung Cancer Diagnosis and Therapeutics Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Lung Cancer Diagnosis and Therapeutics Market Share (2019-2020)
Table 52. Japan Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Lung Cancer Diagnosis and Therapeutics Market Share by Type (2015-2020)
Table 54. Japan Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Lung Cancer Diagnosis and Therapeutics Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Lung Cancer Diagnosis and Therapeutics Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Lung Cancer Diagnosis and Therapeutics Market Share (2019-2020)
Table 58. Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Share by Type (2015-2020)
Table 60. Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Share by Application (2015-2020)
Table 62. India Key Players Lung Cancer Diagnosis and Therapeutics Revenue (2019-2020) (Million US$)
Table 63. India Key Players Lung Cancer Diagnosis and Therapeutics Market Share (2019-2020)
Table 64. India Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 65. India Lung Cancer Diagnosis and Therapeutics Market Share by Type (2015-2020)
Table 66. India Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 67. India Lung Cancer Diagnosis and Therapeutics Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Lung Cancer Diagnosis and Therapeutics Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Lung Cancer Diagnosis and Therapeutics Market Share (2019-2020)
Table 70. Central & South America Lung Cancer Diagnosis and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Lung Cancer Diagnosis and Therapeutics Market Share by Type (2015-2020)
Table 72. Central & South America Lung Cancer Diagnosis and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Lung Cancer Diagnosis and Therapeutics Market Share by Application (2015-2020)
Table 74. AstraZeneca Company Details
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Product
Table 77. AstraZeneca Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 78. AstraZeneca Recent Development
Table 79. Eli Lilly Company Details
Table 80. Eli Lilly Business Overview
Table 81. Eli Lilly Product
Table 82. Eli Lilly Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 83. Eli Lilly Recent Development
Table 84. Sanofi Company Details
Table 85. Sanofi Business Overview
Table 86. Sanofi Product
Table 87. Sanofi Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 88. Sanofi Recent Development
Table 89. ArQule Company Details
Table 90. ArQule Business Overview
Table 91. ArQule Product
Table 92. ArQule Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 93. ArQule Recent Development
Table 94. Daiichi Sankyo Company Details
Table 95. Daiichi Sankyo Business Overview
Table 96. Daiichi Sankyo Product
Table 97. Daiichi Sankyo Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 98. Daiichi Sankyo Recent Development
Table 99. Celgene Company Details
Table 100. Celgene Business Overview
Table 101. Celgene Product
Table 102. Celgene Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 103. Celgene Recent Development
Table 104. Merck Company Details
Table 105. Merck Business Overview
Table 106. Merck Product
Table 107. Merck Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 108. Merck Recent Development
Table 109. Pfizer Business Overview
Table 110. Pfizer Product
Table 111. Pfizer Company Details
Table 112. Pfizer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 113. Pfizer Recent Development
Table 114. Boehringer Ingelheim Company Details
Table 115. Boehringer Ingelheim Business Overview
Table 116. Boehringer Ingelheim Product
Table 117. Boehringer Ingelheim Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 118. Boehringer Ingelheim Recent Development
Table 119. Roche Company Details
Table 120. Roche Business Overview
Table 121. Roche Product
Table 122. Roche Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 123. Roche Recent Development
Table 124. Genentech Company Details
Table 125. Genentech Business Overview
Table 126. Genentech Product
Table 127. Genentech Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 128. Genentech Recent Development
Table 129. GSK Company Details
Table 130. GSK Business Overview
Table 131. GSK Product
Table 132. GSK Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 133. GSK Recent Development
Table 134. Pharmacyclics Company Details
Table 135. Pharmacyclics Business Overview
Table 136. Pharmacyclics Product
Table 137. Pharmacyclics Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 138. Pharmacyclics Recent Development
Table 139. Novartis Company Details
Table 140. Novartis Business Overview
Table 141. Novartis Product
Table 142. Novartis Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 143. Novartis Recent Development
Table 144. Bayer Company Details
Table 145. Bayer Business Overview
Table 146. Bayer Product
Table 147. Bayer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 148. Bayer Recent Development
Table 149. Bristol-Myers Squibb Company Details
Table 150. Bristol-Myers Squibb Business Overview
Table 151. Bristol-Myers Squibb Product
Table 152. Bristol-Myers Squibb Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 153. Bristol-Myers Squibb Recent Development
Table 154. Eisai Company Details
Table 155. Eisai Business Overview
Table 156. Eisai Product
Table 157. Eisai Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 158. Eisai Recent Development
Table 159. AbbVie Company Details
Table 160. AbbVie Business Overview
Table 161. AbbVie Product
Table 162. AbbVie Revenue in Lung Cancer Diagnosis and Therapeutics Business (2015-2020) (Million US$)
Table 163. AbbVie Recent Development
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Lung Cancer Diagnosis and Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Non-Small Cell Lung Cancer Features
Figure 3. Small Cell Lung Cancer Features
Figure 4. Global Lung Cancer Diagnosis and Therapeutics Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Cancer Research Centers Case Studies
Figure 7. Lung Cancer Diagnosis and Therapeutics Report Years Considered
Figure 8. Global Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 9. Global Lung Cancer Diagnosis and Therapeutics Market Share by Regions: 2020 VS 2026
Figure 10. Global Lung Cancer Diagnosis and Therapeutics Market Share by Regions (2021-2026)
Figure 11. Porter's Five Forces Analysis
Figure 12. Global Lung Cancer Diagnosis and Therapeutics Market Share by Players in 2019
Figure 13. Global Top Lung Cancer Diagnosis and Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lung Cancer Diagnosis and Therapeutics as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Lung Cancer Diagnosis and Therapeutics Revenue in 2019
Figure 15. North America Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 16. Europe Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. China Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Japan Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. India Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Central & South America Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Bottom-up and Top-down Approaches for This Report
Figure 23. Data Triangulation
Figure 24. Key Executives Interviewed
非小細胞肺がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Non-small Cell Lung Cancer Therapeutics Market The global Non-small Cell Lung Cancer Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Non-small Cell Lung Cancer Therapeu…- 小細胞肺がん治療薬の世界市場（～2026年） Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell car…
- 小細胞肺がん治療の世界市場（～2026年） Market Analysis and Insights: Global Small Cell Lung Cancer Treatment Market The global Small Cell Lung Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Small Cell Lung Cancer Treatment Scope and Market…
- 肺がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Lung Cancer Therapeutics Market The global Lung Cancer Therapeutics market size is projected to reach US$ 15800 million by 2026, from US$ 14180 million in 2020, at a CAGR of 10.6%% during 2021-2026. Global Lung Cancer Therapeutics Scope and Market Size Lung Cance…
- 肺癌の世界市場（～2026年） Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Most cancers that start in the lung, known as prim…